Zacks Investment Research cut shares of Edap Tms (NASDAQ:EDAP) from a hold rating to a sell rating in a report published on Friday morning.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Several other analysts have also recently issued reports on the stock. HC Wainwright reissued a buy rating on shares of Edap Tms in a research report on Tuesday, September 4th. ValuEngine raised shares of Edap Tms from a hold rating to a buy rating in a research report on Monday, July 16th. Finally, TheStreet raised shares of Edap Tms from a d+ rating to a c rating in a research report on Tuesday, June 26th.

Shares of EDAP opened at $2.86 on Friday. Edap Tms has a 1 year low of $2.07 and a 1 year high of $4.25. The company has a current ratio of 2.45, a quick ratio of 2.04 and a debt-to-equity ratio of 0.05.

Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings results on Wednesday, August 29th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). The business had revenue of $10.14 million for the quarter, compared to analyst estimates of $10.74 million. Edap Tms had a negative return on equity of 4.04% and a negative net margin of 3.55%. research analysts forecast that Edap Tms will post -0.03 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Edap Tms stock. Archon Capital Management LLC boosted its position in Edap Tms SA (NASDAQ:EDAP) by 7.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,019,011 shares of the medical equipment provider’s stock after acquiring an additional 71,336 shares during the quarter. Edap Tms accounts for about 0.2% of Archon Capital Management LLC’s holdings, making the stock its 14th biggest holding. Archon Capital Management LLC owned 3.51% of Edap Tms worth $2,364,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.13% of the company’s stock.

About Edap Tms

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Recommended Story: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with's FREE daily email newsletter.